The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.
 
Daniel Walden
No Relationships to Disclose
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Joseph J. Larson
Employment - Amazing You Therapy (I)
Leadership - Amazing You Therapy (I)
Stock and Other Ownership Interests - Amazing You Therapy (I)
 
Christina Wu
Honoraria - Oncology Learning Network; PrecisCA
Consulting or Advisory Role - Array BioPHarma; Natera; Nova Research Company
Research Funding - Boston Biomedical (Inst); InhibRx (Inst); Lycera (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Sandra Kang
No Relationships to Disclose
 
Alex John Liu
No Relationships to Disclose
 
Cassia R Griswold
Research Funding - Bayer (Inst)
 
Benjamin Edward Ueberroth
No Relationships to Disclose
 
Bhamini Patel
No Relationships to Disclose
 
Amber Draper
No Relationships to Disclose
 
Kelley Rone
No Relationships to Disclose
 
Puneet Raman
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Daniel H. Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer